Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
540 participants
INTERVENTIONAL
2013-08-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
NCT02108184
A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection
NCT01219764
Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication
NCT02827942
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
NCT00197418
Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
NCT02352701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* 170 subjects per group
* Eradication regimens are as follows: AOC group, treated with amoxicillin, rabeprazole, clarithromycin for 7 days; AOM group, treated with amoxicillin, rabeprazole, metronidazole for 7 days; sequential group, treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days; concomitant group, treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AOC group
AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
amoxicillin, clarithromycin, metronidazole, rabeprazole
AOM group
AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
amoxicillin, clarithromycin, metronidazole, rabeprazole
Sequential group
Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
amoxicillin, clarithromycin, metronidazole, rabeprazole
concomitant group
concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
amoxicillin, clarithromycin, metronidazole, rabeprazole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amoxicillin, clarithromycin, metronidazole, rabeprazole
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnancy
* formerly treated with eradication
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bucheon St. Mary's Hospital
OTHER
St Vincent's Hospital
OTHER
The Catholic University of Korea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jin Il Kim
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yeouido St. Mary's Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
concomitant
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.